Norges Bank’s Sutro Biopharma STRO Stock Holding History

Norges Bank’s Portfolio STRO Stock Details STRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-12,490	Closed	-$577K	–	2109
2023 Q1	$577K	Sell	12,490 -8,130	-39%	-$516K	﹤0.01%	2041
2022 Q4	$1.67M	Buy	+20,620	New	+$1.43M	﹤0.01%	1993

Other funds holding STRO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Norges Bank's STRO Position: Q2 2023 in Review

Norges Bank sold out of Sutro Biopharma (STRO) in Q2 2023, closing a stake of 12,490 shares — an estimated $577K sold.

Norges Bank first reported a position in STRO in Q4 2022 and held it in 2 quarters. The position peaked at $1.67M in Q4 2022. 120 funds tracked by Wall St. Rank hold STRO as of Q2 2023.

Norges Bank reported no remaining Sutro Biopharma position as of Q2 2023 after selling out during the quarter.
Norges Bank sold 12,490 Sutro Biopharma shares in Q2 2023, an estimated $577K.
Norges Bank first reported a position in Sutro Biopharma in Q4 2022 and held it in 2 quarters.
Norges Bank's Sutro Biopharma position peaked at $1.67M in Q4 2022.
120 funds tracked by Wall St. Rank held Sutro Biopharma as of Q2 2023.

Based on Norges Bank's 13F filing for Q2 2023, filed 14 Aug 2023.